Saturday 17 October 2026
Export XERS’s income statement to Excel — free account
Xeris Biopharma Holdings, Inc.
XERS Healthcare Drug Manufacturers Specialty & Generic
Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024. In the quarter to June 2026, revenue grew 28.7%, EPS fell 1,700.0%, free cash flow grew 8,403.1% and total debt rose 15.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
10.31
0.24
+2.38%
Follow XERS
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2,065.79 |
Piotroski F-Score |
— | — | 3 | 1 | 5 | 5 | 4 | 5 | 4 | 8 |
Altman Z-Score |
— | — | 0.81 | (5.01) | (2.63) | (2.29) | (1.96) | (1.80) | (1.53) | 0.98 |
P/S ratio |
0.00 | 0.00 | 84.52 | 67.63 | 10.27 | 4.67 | 1.38 | 1.91 | 2.45 | 4.32 |
Altman Z″-Score (non-manufacturers) |
12.69 | 5.84 | 1.06 | (11.13) | (5.04) | (5.62) | (4.53) | (5.93) | (6.20) | (2.99) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 45.09 |
Beneish M-Score |
— | 4.77 | (2.83) | 60.79 | 1.89 | 139.26 | (1.67) | (2.38) | (2.72) | (2.58) |
P/Operating CF |
(5.62) | (5.62) | (11.17) | (6.22) | (19.30) | (8.00) | (9.42) | 41.83 | 251.93 | 62.83 |
P/B ratio |
0.00 | 0.00 | 2.72 | 12.75 | 6.21 | 2.43 | 3.36 | 0.00 | 0.00 | 92.00 |
Price to Tangible BV |
0.00 | 0.00 | 2.72 | 12.75 | 6.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 51.19 | 62.39 | 8.13 | 4.44 | 1.98 | 2.64 | 3.24 | 4.73 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 33.70 |
EV/Operating CF |
(0.36) | (0.36) | (2.20) | (1.63) | (2.06) | (2.30) | (2.12) | (9.22) | (17.79) | 48.23 |
EV/FCF |
(0.35) | (0.35) | (2.15) | (1.61) | (2.05) | (2.28) | (2.11) | (8.79) | (17.39) | 49.43 |
Quick Ratio |
12.81 | 8.90 | 11.35 | 2.94 | 4.99 | 1.52 | 2.08 | 1.17 | 1.12 | 1.48 |
Current Ratio |
13.13 | 9.06 | 11.59 | 3.20 | 5.40 | 1.80 | 2.54 | 1.64 | 1.67 | 2.19 |
Net Debt/EBITDA |
2.46 | 1.59 | 1.38 | 0.14 | 0.58 | 0.13 | (0.98) | (4.14) | (8.91) | 2.67 |
Debt/Assets |
0.00% | 0.00% | 26.57% | 53.50% | 54.68% | 28.94% | 54.76% | 59.19% | 71.85% | 57.45% |
Debt/Equity |
0.00 | 0.00 | 0.42 | 4.04 | 2.58 | 0.92 | 4.18 | (28.15) | (7.84) | 16.10 |
Asset Turnover |
0.03 | 0.04 | 0.03 | 0.02 | 0.15 | 0.21 | 0.34 | 0.49 | 0.63 | 0.83 |
Operating CF/Net income |
1.22 | 0.93 | 0.94 | 0.83 | 0.88 | 0.78 | 1.09 | 0.76 | 0.67 | 51.67 |
Capex/Depreciation |
(0.30) | (3.11) | (1.72) | (0.55) | (0.15) | (0.38) | (0.04) | (0.15) | (0.06) | (0.04) |
Interest Coverage |
(6,615.50) | (13,314.50) | (23.32) | (17.08) | (7.84) | (16.04) | (5.81) | (1.65) | (1.10) | 0.86 |
| 29.43% | 59.16% | (683.66%) | (279.56%) | (378.20%) | (190.28%) | (134.83%) | (324.20%) | 301.32% | (6.96%) | |
| (33.64%) | (67.63%) | (72.81%) | (109.67%) | (67.98%) | (52.95%) | (29.18%) | (18.66%) | (16.99%) | 0.16% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (89.00%) | (45.78%) | (24.63%) | (16.07%) | 12.65% |
Return on Tangible Assets |
(42.67%) | (66.42%) | (54.74%) | (184.68%) | (69.73%) | (174.86%) | (79.74%) | (92.86%) | (75.34%) | 0.41% |
Average Days of Receivables |
34.29 | 281.26 | 432.19 | 629.30 | 122.80 | 128.48 | 102.07 | 87.28 | 72.64 | 63.85 |
Research and Development Expense of Revenue |
952.37% | 1,296.02% | 1,677.84% | 2,220.35% | 102.38% | 50.74% | 19.02% | 13.63% | 12.59% | 10.68% |
Selling, General and Administrative Expense of Revenue |
377.67% | 515.10% | 871.36% | 2,316.72% | 360.81% | 253.51% | 124.94% | 89.13% | 80.50% | 62.49% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.51 | 0.42 | 0.41 | 0.38 | 0.29 |
Share Based Compensation of Revenue |
50.23% | 32.07% | 71.32% | 238.21% | 40.48% | 22.95% | 11.03% | 6.54% | 9.04% | 7.66% |
Graham Net Nets |
0.76 | 0.76 | 0.36 | (0.04) | 0.13 | (0.29) | (0.74) | (0.55) | (0.37) | (0.10) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.71 | 1.31 | 0.09 |
Earnings Yield |
(9.55%) | (9.55%) | (60.28%) | (68.09%) | (46.34%) | (51.88%) | (62.50%) | (19.82%) | (11.21%) | 0.05% |
Free Cash Flow Yield |
(76.34%) | (76.34%) | (28.22%) | (57.29%) | (38.58%) | (41.73%) | (68.08%) | (15.77%) | (7.61%) | 2.22% |
Revenue per Share |
0.58 | 0.77 | 0.20 | 0.10 | 0.48 | 0.63 | 0.81 | 1.19 | 1.38 | 1.82 |
Operating CF per Share |
(8.73) | (12.16) | (4.67) | (4.00) | (1.89) | (1.21) | (0.76) | (0.34) | (0.25) | 0.18 |
Capex per Share |
(0.02) | (0.35) | (0.13) | (0.04) | (0.01) | (0.01) | 0.00 | (0.02) | (0.01) | 0.00 |
Free Cash Flow per Share |
(8.75) | (12.51) | (4.80) | (4.04) | (1.90) | (1.22) | (0.76) | (0.36) | (0.26) | 0.17 |
Cash per Share |
17.52 | 20.73 | 9.35 | 2.89 | 3.14 | 1.30 | 0.90 | 0.53 | 0.49 | 0.69 |
Shareholders Equity per Share |
16.81 | 19.75 | 6.26 | 0.55 | 0.79 | 1.21 | 0.33 | (0.05) | (0.20) | 0.09 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
16.81 | 19.75 | 6.26 | 0.55 | 0.79 | 1.21 | 0.33 | (0.05) | (0.20) | 0.09 |
Free Cash Flow |
(16.12) | (25.36) | (57.79) | (105.45) | (80.93) | (96.62) | (103.41) | (49.29) | (37.85) | 27.93 |
Working Capital |
30.65 | 39.19 | 107.73 | 60.15 | 124.01 | 63.56 | 113.20 | 61.07 | 67.22 | 130.74 |
Capital Expenditures |
(0.03) | (0.70) | (1.51) | (1.11) | (0.38) | (1.08) | (0.52) | (2.26) | (0.87) | (0.70) |
Net Current Asset Value |
30.61 | 39.10 | 73.28 | (7.07) | 26.82 | (66.53) | (112.52) | (173.12) | (185.01) | (129.52) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 55.45 |
Capex to Sales |
0.03 | 0.45 | 0.62 | 0.41 | 0.02 | 0.02 | 0.00 | 0.01 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 50.58 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.37 | 0.29 | 0.43 | 0.26 | 0.36 | 0.43 | 2.58 | 2.57 | 2.81 | 3.25 |
Cash ROIC |
(25.50%) | (30.90%) | (26.28%) | (71.11%) | (31.79%) | (33.82%) | (29.06%) | (19.21%) | (13.81%) | 8.09% |
Accounts Receivable Turnover |
1.65 | 2.39 | 1.19 | 0.72 | 3.53 | 4.08 | 4.57 | 4.68 | 5.10 | 6.38 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.23 | 0.50 | 2.14 | 2.21 | 3.35 | 3.54 | 5.32 | 15.87 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.30 | 1.77 | 1.01 | 1.06 | 0.90 | 0.85 | 0.73 |
Average Days of Payables |
59,996.88 | 180,310.00 | 987.78 | 1,275.79 | 121.97 | 244.58 | 74.28 | 147.36 | 22.69 | 26.37 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 495.47 | 326.85 | 496.55 | 398.88 | 494.88 | 477.41 | 588.82 |
Average Receivables |
0.65 | 0.65 | 2.03 | 3.78 | 5.78 | 12.17 | 24.14 | 35.01 | 39.81 | 45.73 |
Average Payables |
1.65 | 1.65 | 1.42 | 3.23 | 4.36 | 6.02 | 6.77 | 8.09 | 6.93 | 2.68 |
Average Inventory |
— | — | — | 5.26 | 5.26 | 13.24 | 21.43 | 31.79 | 43.51 | 58.42 |
Average Assets |
39.27 | 39.27 | 82.51 | 114.51 | 134.07 | 231.76 | 324.44 | 333.56 | 322.83 | 353.29 |
Average Common Equity |
(44.88) | (44.88) | 8.79 | 44.92 | 24.10 | 64.50 | 70.21 | 19.20 | (18.20) | (7.96) |
Columns are period end dates